Also this average forecast of 1015 represents a -2734 decrease from the past average forecast of 13969 6 months ago from 13 wall street analysts. Thus investors eager to increase their holdings of the companys stock will have an opportunity to do so as the average rating for the stock is.
Sarepta specializes in gene therapies to treat rare neurological disorders.
Srpt stock. Common Stock DE SRPT Nasdaq Listed. Sarepta Therapeutics Inc. Share your opinion and gain insight from other stock traders and investors.
The average Sarepta Therapeutics stock forecast from last 6 month is 1015 and this show a -211 decrease in average from the prior price target of the each prediction. NASDAQSRPT the leader in precision genetic medicine for rare diseases today announced that it has priced an underwritten public offering of 6172840 shares of its common stock at a price to the public of 8100 per share. In addition Sarepta has granted the.
051 056 CLOSED AT 400 PM ET ON Sep 27 2021. CAMBRIDGE Mass Oct. The stock dropped more than 13 a share over the course of the week.
SRPT stock was sold by a variety of institutional investors in the last quarter including NEXT Financial Group Inc and Focused Wealth Management Inc. View live Sarepta Therapeutics Inc chart to track its stocks price action. The stock is rated as a Hold by 7 analysts 11 recommend it as a Buy and 2 called the SRPT stock Overweight.
SRPT Complete Sarepta Therapeutics Inc. Sarepta Therapeutics NASDAQSRPT a biotech. NASDAQSRPT went up by 470 from its latest closing price compared to the recent 1-year high of 18183.
In the meantime 0 analysts believe the stock as Underweight and 0 think it is a Sell. Sarepta Therapeutics Inc. The company was founded on July 22 1980 and is headquartered in Cambridge MA.
Unfortunately SRPT wasnt nearly as popular as these 30 stocks and hedge funds that were betting on SRPT were disappointed as the stock returned -553 since the end of. The company report on October 14 2021 that Sarepta Therapeutics Announces Pricing. The days price range saw the stock hit a low of 8227 while the highest price level was 8575.
Data is currently not available. 8 hours ago – Why Sarepta Therapeutics Fell 147 This Week – The Motley Fool11 hours ago – 4 Biotechs to Watch Amid Rising Prominence of Gene Therapies – Zacks Investment Research1 day ago – Sarepta Therapeutics Announces Pricing of 500 Million Public Offering of Common Stock – GlobeNewsWire. Press Release reported on 091421 that Sarepta Therapeutics to Showcase Data from its Gene Therapy and RNA Platforms at World Muscle Society 2021 Virtual.
The stock is rated as a Hold by 6 analysts 13 recommend it as a Buy and 1 called the SRPT stock Overweight. Get the latest Sarepta Therapeutics stock price and detailed information including SRPT news historical charts and realtime prices. According to the issued ratings of 21 analysts in the last year the consensus rating for Sarepta Therapeutics stock is Buy based on the current 9 hold ratings and 12 buy ratings for SRPT.
View real-time stock prices and stock quotes for a full financial overview. Thus investors eager to increase their holdings of the companys stock will have an opportunity to do so as the average rating for the stock is. NASDAQ Updated Oct 15 2021 1155 PM SRPT 8419 119 143.
Sarepta Therapeutics stock forecast by Wall Street Analysts. In the meantime 0 analysts believe the stock as Underweight and 0 think it is a Sell. The average twelve-month price target for Sarepta Therapeutics is 13265 with a high price target of 21500 and a low price target of 7500.
Sarepta Therapeutics Inc. 13 2021 GLOBE NEWSWIRE — Sarepta Therapeutics Inc. Research and ratings by Barrons.
Shares touched a four-month high relieving some of the pressure. Sarepta Therapeutics Inc. Is a commercial-stage biopharmaceutical company which is engaged in the discovery and development of therapeutics for the treatment of rare diseases.
If an investor was to purchase shares of SRPT stock at the current price. Find market predictions SRPT financials and market news. Company insiders that have sold Sarepta Therapeutics company stock in the last year include Hans Lennart Rudolf Wigzell Joseph Bratica and M Kathleen Behrens.
350 rows Analyst Price Target for SRPT i We calculate consensus analyst ratings for stocks using the. On todays stock market SRPT stock soared 314 to 13205 in massive volume. View SRPT revenue estimates and earnings estimates as well as in-depth analyst breakdowns.
Sarepta Therapeutics Inc. The companys stock price has collected 738 of gains in the last five trading sessions. SRPT stock discussion in Yahoo Finances forum.
SRPT closed the trading session at 8300 on 101421. Find the latest Sarepta Therapeutics Inc. Turning to the calls side of the option chain the call contract at the 8100 strike price has a current bid of 500.
Stock news by MarketWatch.